lnvestigation of cell migration effects of tekamen and methotrexate on MDA-MB 231 breast Gancer cell line

Abstract

Background: Combinatian therapy, a treatment modaiity that combines two or more therapeutic agents, is a cornerstone of cancer therapy. Tekamen has topoisomerase l activity by stabilizing the cleavable complex between topoisomerase l and DNA, resulting in DNA breaks that inhibit DNA replicatlon and,trigger-apoptotlc cell death. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resultİng İn inhİbition of purine nucleotİde and ihymidylate synthesis and, subsequent|y, inhibition of DNA and RNA syntheses. Combined treatment can provide benefit and reducing side effects of drugs. The aim of this study is to understand effects of Tekamen and Methotrexate on cell migration on MDA-MB-231 breast cancer cell line. Methods; Cell viabil§ was measured by MTT assay100 pM Tekamen for wound healinç the MDA-MB- 231 cell line was cultured being 1d cells in 1S pL in a 6-well culture plate. After cells have 90% confluency, cetts treated with 100 pM Tekamen, 60 ptM Methotrexate and 75 pM Tekamen+ 60 pM Methotrexate. Widths of scar were observed at 0, 24,48 and 72 hours by inverted microscope. Results: We compared effect of monotherapy and polytherapy of drugs on cell migration and wound size drug-applied breast cancer cell line to control group. We observered amount of cell viabilties after drug treatment are 5413ğ for 100pM tekamen,40,89}6 for 6OpM Methotrexate and 59,47% for 75 pM Tekamen+ 60 pM Methotrexate combine treatment. We observed to inhibit cell migration with combine treatment at for 72 hours. These results show that combine therapy is more effective than monotherapy because cancer cells are less to have resistance to muttiple drugs treatment and this approach,increases }he chance'of effective treatment.